Gene Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRXM research report →
Companygenebiotherapeutics.com
Gene Biotherapeutics, Inc. , a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
- CEO
- Christopher J. Reinhard
- IPO
- 2000
- Employees
- 3
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $6.49K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 12.69%
- ROIC
- 38.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-518,000 · -159.77%
- EPS
- $-0.02 · -139.97%
- Op Income
- $-1,262,000
- FCF YoY
- -728.54%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 19.29
- Avg Volume
- 0
Get TickerSpark's AI analysis on CRXM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 21 | Jemapete Christopher J | other | 0 |
| Mar 17, 21 | Jemapete Christopher J | buy | 200,000 |
| Mar 16, 21 | Jemapete Christopher J | buy | 300,000 |
| Feb 26, 21 | Jemapete Christopher J | other | 0 |
| Mar 23, 15 | HUTCHISON MURRAY H | other | 50,000 |
| Mar 23, 15 | Leitch Andrew M | other | 50,000 |
| Feb 28, 14 | HUTCHISON MURRAY H | other | 50,000 |
| Feb 28, 14 | Leitch Andrew M | other | 50,000 |
| Feb 28, 14 | MULROY DENNIS | other | 50,000 |
Our CRXM Coverage
We haven't published any research on CRXM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRXM Report →